Last reviewed · How we verify
Single group, open-label
Unable to determine specific mechanism without drug name or identifier.
At a glance
| Generic name | Single group, open-label |
|---|---|
| Also known as | ADCTA-G |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Biologic |
| Phase | FDA-approved |
Mechanism of action
Insufficient information provided to characterize the molecular mechanism of action. The submission includes only study design (single group, open-label), company affiliation (Daewoong Pharmaceutical Co. LTD.), and phase (marketed), but lacks the drug name, brand name, or molecular target necessary to establish mechanism.
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers (PHASE1)
- A Pharmacokinetic Study of VCT220 With Moderate Renal Impairment Patients (PHASE1)
- Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. (PHASE2)
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). (PHASE2, PHASE3)
- Reconfirming the Safety and Performance of the Glyconics-DS System in Known Populations With and Without Diabetes (NA)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Management of Catatonic Features in Adolescents With Profound Autism (NA)
- A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Single group, open-label CI brief — competitive landscape report
- Single group, open-label updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI